Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 184, Issue -, Pages 325-338Publisher
ELSEVIER
DOI: 10.1016/j.ijbiomac.2021.06.014
Keywords
PEGylated chitosan nanoparticle; Anti-HER2 monoclonal antibody; Doxorubicin targeted drug delivery
Funding
- American University in Cairo, Egypt
Ask authors/readers for more resources
Breast cancer is a top chronic and life-threatening disease worldwide. Nano-drug therapeutic systems using biodegradable chitosan nanoparticles (CSNPs) have shown efficacy in providing selective and sustained release of drugs within the breast tumor microenvironment. Functionalizing CSNPs with breast cancer-specific monoclonal antibodies (mAb) has demonstrated high cytotoxicity against cancer cells.
Breast cancer has been one of the top chronic and life-threatening diseases worldwide. Nano-drug therapeutic systems have proved their efficacy as a selective treatment compared to the traditional ones that are associated with serious adverse effects. Here, biodegradable chitosan nanoparticles (CSNPs) were synthesized to provide selective and sustained release of doxorubicin (DOX) within the breast tumor microenvironment. CSNPs surface was modified using Polyethylene glycol (PEG) to enhance their blood circulation timing. To provide high drug selectivity, CSNPs functionalized with two different types of breast cancer-specific monoclonal antibodies (mAb); anti-human mammaglobin (Anti-hMAM) and anti-human epidermal growth factor (Anti-HER2). Anti-hMAM PEGylated DOX loaded CSNPs and Anti-HER2 PEGylated DOX loaded CSNPs nano-formulations were the most cytotoxic against MCF-7 cancer cells than L-929 normal cells compared to free DOX. Finally, we believe that dose-dependent system toxicity of freely ingested DOX can be managed with such targeted nano-formulated drug delivery platforms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available